Nanovaccine trains immune cells to hunt lung cancer

NCT ID NCT07239544

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new way to create tumor-reactive T cells for people with non-small cell lung cancer. Researchers use a nanovaccine made from lung cancer antigens to train T cells to attack the cancer. The goal is to see if these T cells can effectively target tumors in lab models and in the body. The study involves 50 participants and focuses on understanding how the T cells behave after being reinfused.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tumor whole cell antigen nanovaccine and tumor-reactive T cells
What this could lead to
If successful, this could lead to a more effective and personalized cell therapy for non-small cell lung cancer, potentially improving tumor targeting and patient outcomes.
What could go wrong
This is an early-stage observational study with only 50 participants, so results may not apply broadly. The approach is complex and may face challenges in effectiveness or safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Soochow university

    Suzhou, Jiangsu, 215000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.